Pyxis Oncology (NASDAQ:PYXS) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Pyxis Oncology (NASDAQ:PYXS) from a hold rating to a sell rating in a research note issued to investors on Friday.

PYXS has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Pyxis Oncology in a research report on Tuesday, August 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Saturday, September 27th. Guggenheim initiated coverage on shares of Pyxis Oncology in a research report on Wednesday, September 3rd. They set a “buy” rating and a $5.00 price objective on the stock. Finally, Zacks Research raised shares of Pyxis Oncology from a “strong sell” rating to a “hold” rating in a research report on Monday, August 18th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pyxis Oncology currently has an average rating of “Hold” and an average price target of $7.75.

Pyxis Oncology Stock Up 14.2%

Shares of NASDAQ PYXS opened at $2.57 on Friday. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.39. The firm’s fifty day moving average is $1.59 and its 200 day moving average is $1.29. The company has a market cap of $159.39 million, a price-to-earnings ratio of -1.61 and a beta of 1.33.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Thursday, August 14th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06. The firm had revenue of $2.82 million during the quarter. Equities research analysts anticipate that Pyxis Oncology will post -1.04 earnings per share for the current year.

Hedge Funds Weigh In On Pyxis Oncology

A number of hedge funds have recently bought and sold shares of PYXS. Jane Street Group LLC purchased a new position in Pyxis Oncology in the 2nd quarter worth about $370,000. Pier 88 Investment Partners LLC raised its position in Pyxis Oncology by 296.6% in the 1st quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company’s stock worth $383,000 after buying an additional 292,370 shares during the last quarter. Schulhoff & Co. Inc. raised its position in Pyxis Oncology by 125.4% in the 2nd quarter. Schulhoff & Co. Inc. now owns 275,000 shares of the company’s stock worth $302,000 after buying an additional 153,000 shares during the last quarter. Marshall Wace LLP purchased a new position in Pyxis Oncology in the 2nd quarter worth about $163,000. Finally, 683 Capital Management LLC raised its position in Pyxis Oncology by 32.5% in the 1st quarter. 683 Capital Management LLC now owns 550,000 shares of the company’s stock worth $539,000 after buying an additional 135,000 shares during the last quarter. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.